DETERMINATION OF PLASMA FIBRONECTIN AND SERUM C‐REACTIVE PROTEIN IN PATIENTS WITH CEREBROVASCULAR EVENTS

The relationship between the levels of C‐reactive protein (CRP) and fibronectin (FN) and atherosclerotic diseases such as coronary heart disease has already been studied, but their relationship with cerebrovascular events has not. The aim of this study was to determine the levels of plasma FN and serum CRP in cerebrovascular events, and their relationship with the outcome of the disease. CRP and FN levels were analysed in 133 patients with acute cerebrovascular disease, together with 66 healthy controls. Cerebrovascular event patients were divided into subgroups according to disease severity. FN and CRP levels in patients with cerebrovascular disease were found to be significantly elevated compared with the control group (p<0.001). CRP levels correlated with disease severity, in contrast to FN levels. We conclude that FN is not a clinically useful marker in patients with acute differentiative cerebrovascular events, in contrast to CRP which may be useful in such cases.

[1]  T. Esch,et al.  Proinflammation: a common denominator or initiator of different pathophysiological disease processes. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[2]  Shyi-Jang Shin,et al.  Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. , 2002, Atherosclerosis.

[3]  R. Balaban,et al.  Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans , 2001, Journal of magnetic resonance imaging : JMRI.

[4]  V. Y. Wong,et al.  Renoprotective effects of carvedilol in hypertensive‐stroke prone rats may involve inhibition of TGFβ expression , 2001, British journal of pharmacology.

[5]  J. B. Lopes de Faria,et al.  The presence of genetic hypertension stimulates early renal accumulation of fibronectin in experimental diabetes mellitus , 2001, Diabetologia.

[6]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[7]  R. Westendorp,et al.  C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy. , 2001, Atherosclerosis.

[8]  M. Hori,et al.  C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis , 2001, Circulation.

[9]  M. Di Napoli,et al.  C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor , 2001, Stroke.

[10]  H. Melzner,et al.  Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans , 2001, Langenbeck’s Archives of Surgery.

[11]  M. Shakibaei,et al.  Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. , 2001, Journal of molecular and cellular cardiology.

[12]  A. Algra,et al.  Plasma levels of cellular fibronectin in diabetes. , 2001, Diabetes care.

[13]  M. Di Napoli.  C reactive protein and acute phase of ischaemic stroke. , 2001, British medical journal.

[14]  Robert,et al.  Plasma fibronectin in French centenarians. , 2000, Archives of gerontology and geriatrics.

[15]  M. Miyazaki,et al.  Dietary docosahexaenoic acid ameliorates, but rapeseed oil and safflower oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-beta, fibronectin and renin. , 2000, Biochimica et biophysica acta.

[16]  S. Werner,et al.  Connective tissue growth factor: a novel player in tissue reorganization after brain injury? , 2000, The European journal of neuroscience.

[17]  M. Di Napoli,et al.  C-reactive protein and outcome after first-ever ischemic stroke. , 2000, Stroke.

[18]  W. Reinhart,et al.  C-reactive protein (CRP) in cerebro-vascular events. , 1999, Atherosclerosis.

[19]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[20]  C. Franzini.  Need for Correct Estimates of Biological Variation: The Example of C-Reactive Protein , 1998, Clinical chemistry and laboratory medicine.

[21]  A. Grau.  Infection, inflammation, and cerebrovascular ischemia , 1997, Neurology.

[22]  A. Alpérovitch,et al.  Cardiovascular determinants of plasma fibronectin in an elderly population: the EVA study. , 1997, Archives of gerontology and geriatrics.

[23]  A. Dirican,et al.  The importance of Lp(a)-fibronectin interaction in atherogenesis. , 1997, Haematologia.

[24]  F. Barone,et al.  The Role of Inflammation and Cytokines in Brain Injury , 1996, Neuroscience & Biobehavioral Reviews.

[25]  N. Bornstein,et al.  Acute infection as a risk factor for ischemic stroke. , 1996, Stroke.

[26]  G. Kwakkel,et al.  Predicting disability in stroke--a critical review of the literature. , 1996, Age and ageing.

[27]  Jong S. Kim.  Cytokines and adhesion molecules in stroke and related diseases , 1996, Journal of the Neurological Sciences.

[28]  M. Glukhova,et al.  Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. , 1993, Hypertension.

[29]  A. Chobanian,et al.  Effect of hypertension on fibronectin expression in the rat aorta. , 1990, The Journal of biological chemistry.

[30]  S. Dedhar,et al.  Immunostaining of human brain capillaries by antibodies to very late antigens , 1990, Journal of Neuroimmunology.

[31]  W. Kuschinsky,et al.  Congruence of total and perfused capillary network in rat brains. , 1990, Circulation research.

[32]  M. S. Gabrielian,et al.  [Fibronectin levels in the blood and cerebrospinal fluid in cerebrovascular diseases]. , 1989, Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova.

[33]  T. Stubbs,et al.  Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. , 1984, American journal of obstetrics and gynecology.

[34]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.